Militia Capital Partners LP Sells 60,000 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Militia Capital Partners LP has significantly reduced its stake in Edwards Lifesciences Corporation by 85.7%, selling 60,000 shares, and now holds only 10,000 shares worth approximately $725,000.
• Recent analyst reports indicate a consensus rating of "Moderate Buy" for Edwards Lifesciences, with an average price target of $86.26, reflecting optimism around the company’s stock performance.
• Edwards Lifesciences reported earnings of $0.67 per share for the last quarter, surpassing expectations and showing a revenue increase of 11.9% year-over-year, totaling $1.53 billion.

Militia Capital Partners LP cut its stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 85.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,000 shares of the medical research company's stock after selling 60,000 shares during the quarter. Militia Capital Partners LP's holdings in Edwards Lifesciences were worth $725,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vega Investment Solutions bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at $27,000. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences in the first quarter valued at $26,000. SouthState Corp bought a new position in shares of Edwards Lifesciences in the first quarter valued at $27,000. Rossby Financial LCC bought a new position in shares of Edwards Lifesciences in the first quarter valued at $29,000. Finally, Costello Asset Management INC bought a new position in shares of Edwards Lifesciences in the first quarter valued at $29,000. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. Truist Financial raised their price objective on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research note on Friday, July 25th. Evercore ISI raised their price objective on shares of Edwards Lifesciences from $77.00 to $80.00 and gave the company an "in-line" rating in a research note on Friday, July 25th. JPMorgan Chase & Co. raised their price objective on shares of Edwards Lifesciences from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Friday, July 25th. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 29th. Finally, Stifel Nicolaus raised their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "buy" rating in a research report on Friday, July 25th. Three investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $86.26.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $78.01 on Friday. The stock has a fifty day simple moving average of $78.91 and a two-hundred day simple moving average of $75.35. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00. The firm has a market cap of $45.80 billion, a price-to-earnings ratio of 11.22, a price-to-earnings-growth ratio of 3.78 and a beta of 1.07. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the company earned $0.70 earnings per share. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the transaction, the insider owned 206,900 shares in the company, valued at $15,565,087. This trade represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders sold 22,014 shares of company stock valued at $1,698,844 in the last quarter. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.